Tuesday, May 08, 2018 2:04:14 PM
I disagree with your first part.
The CEO assumes legal responsibilities and accountability. The CEO who's there at the end always shares some of the blame. Seymour will claim to have done a fantastic job setting things up for the next stage, with non-toxic and viable candidates ready to go. All that's needed is for someone who has experience in taking drugs through clinical development to step up, and enjoy the easy ride to success courtesy of Seymour.
Nobody sane walks into a nearly broke mess like this, set up in such an overtly corrupt way to benefit the largest shareholder at the expense of all other shareholders. It's volunteering to spend the next few years of your life embroiled in various lawsuits. With less than a year's worth of salary, to boot.
Nobody who cares about their reputation as a CEO, capable of moving pharma startups from research projects to successful drug developers would do it. Telling future prospective investors in future projects that "it wasn't my fault, it was the other guy's" doesn't work well. At best it shows very poor judgement.
It's probably all theoretical, as you've said. The only one Diwan would want besides himself to be CEO is his wife.
The CEO assumes legal responsibilities and accountability. The CEO who's there at the end always shares some of the blame. Seymour will claim to have done a fantastic job setting things up for the next stage, with non-toxic and viable candidates ready to go. All that's needed is for someone who has experience in taking drugs through clinical development to step up, and enjoy the easy ride to success courtesy of Seymour.
Nobody sane walks into a nearly broke mess like this, set up in such an overtly corrupt way to benefit the largest shareholder at the expense of all other shareholders. It's volunteering to spend the next few years of your life embroiled in various lawsuits. With less than a year's worth of salary, to boot.
Nobody who cares about their reputation as a CEO, capable of moving pharma startups from research projects to successful drug developers would do it. Telling future prospective investors in future projects that "it wasn't my fault, it was the other guy's" doesn't work well. At best it shows very poor judgement.
It's probably all theoretical, as you've said. The only one Diwan would want besides himself to be CEO is his wife.
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
